AxoGen (AXGN) is a medical technology company dedicated to peripheral nerve repair.
AXGN's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.
In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
AXGN provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally.
AxoGen, Inc. is headquartered in Alachua, Florida.
November 8, 2022
RegMed Investors’ (RMi) pre-open: vote your conscious and your portfolio
November 7, 2022
RegMed Investors’ (RMi) closing bell: election and economics will determine the week as negative momentum moves the sector today
November 7, 2022
RegMed Investors’ (RMi) pre-open: the cell and gene therapy sector is stuck in earnings LPS (loss-per-share) season
November 4, 2022
RegMed Investors’ (RMi) closing bell: strolling a crooked session (10 of 35 covered companies stumbled)
November 4, 2022
RegMed Investors’ (RMi) pre-open: We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies
November 3, 2022
RegMed Investors’ (RMi) closing bell: taking it in the shins as sector trips
November 3, 2022
RegMed Investors’ (RMi) pre-open: gains followed by pain; so, what’s on-tap - earnings
November 2, 2022
RegMed Investors’ (RMi) closing bell: We waited for Jerome and got the expected .75 basis point rate increase
November 2, 2022
RegMed Investors’ (RMi) pre-open: bracing for Fed’s policy decision
November 1, 2022
RegMed Investors’ (RMi) closing bell: markets dive as sector thrives, algorithms “rule’ in our favor
35 companies, 1 interpreter!
Insight, foresight and recommendation
AxoGen, Inc. (AXGN) – January '18 opened at $27.95 with an upside of $28.05 on 2/1 while dropping to $27.40 on 2/16 ... since November of '17 appreciation has withstood mild drags to the downside ...
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.